Longeveron Stock News

Longeveron press release (LGVN): Q4 GAAP EPS of -$0.20 beats by $0.05.Revenue of $0.21M (-82.2% Y/Y).CEO comment: “Since our IPO in February of last year, important progress has…

Companies Reporting Before The Bell • The Real Good Food (NASDAQ: RGF ) is estimated to report quarterly loss at $0.19 per share on revenue of $25.29 million. • Smart Share Global (NASDAQ: EM ) is expected to report quarterly loss at $0.04 per share on revenue of $129.31 million. • Longeveron (NASDAQ: LGVN ) is projected to report quarterly loss at $0.25 per share on revenue of $260.00 thousand. • Sunworks (NASDAQ: SUNW ) is likely to report quarterly loss at $0.17 per share on revenue of $31.40 million. • Drive Shack (NYSE: DS ) is likely to report quarterly loss at $0.13 per share on revenue of $69.26 million. • Hudson Global (NASDAQ: HSON ) is likely to report quarterly earnings at $0.46 per share on revenue of $46.25 million. • RLX Technology (NYSE: Full story available on Benzinga.com

Longeveron Inc. (NASDAQ:LGVN) with the stream of -1.84% also noticed, India Denison Mines Corp. (AMEX:DNN) encountered a rapid change of 1.73% in the last hour of Thursday’s trading session. Longeveron … The post Foreshadowing Stock: Longeveron Inc. (NASDAQ:LGVN), Denison Mines Corp. (AMEX:DNN) appeared first on Stocks Equity .

Shares of clinical stage biotechnology company Longeveron Inc. (LGVN) are climbing more than 10% Thursday morning ahead of fourth quarter results, which is scheduled to report on Friday, March 11, before the market opens.

Longeveron is rising before the release of its Q4 2021 earnings report. Here's what investors should know about LGVN stock and why.

The shares of Longeveron (LGVN) a clinical-stage biotechnology company focused on cellular therapies have risen sharply on Wednesday ahead of its Q4 2021 results scheduled for…

Live Conference Call At 8:30 a.m. EST Live Conference Call At 8:30 a.m. EST

Longeveron obtained Rare Pediatric Designation of Lomecel-B for patients with hypoplastic left heart syndrome. All 10 patients who received Lomecel-B were alive and had not required a transplant betwe

When insiders buy a stock, you should take it as a sign that they think good news is about to come out. Here are three to watch closely.

MIAMI, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN ) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today publication of the design and rationale from its recently completed Phase 2b aging frailty clinical trial with Lomecel-B in the Journal of Frailty and Aging . This peer-reviewed article describes the design of the trial which investigated Lomecel-B, a living cell therapy product, as a regenerative medicine strategy for the treatment of frailty in older adults. As a life-threatening geriatric condition, aging frailty affects up to 15% of Americans over the age of 65, or 8.1 million individuals, and manifests as a loss of muscle and decreased strength, slowed walking, low activity and energy levels, poor endurance, nutritional deficiencies, weight loss and fatigue. "There is increasing recognition of the unmet medical need in treating and preventing frailty in older adults, and we feel the acceptance of our trial design and rationale for publication in this prestigious, peer-reviewed journal reflects the urgency to develop potential new therapies," said Geoff Green, CEO of Longeveron.

      Longeveron Announces Initiation of Phase 2a Clinical Trial of Lomecel-B for the Treatment of Alzheimer's Disease   Trial designed to obtain safety and efficacy data of single and multiple dosing regimen   Miami, Florida—January 5, 2021 -- InvestorsHub NewsWire -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic ag...

Investors are reacting positively to the beginning of an Alzheimer's disease trial with Longeveron's lead candidate, Lomadel-B.

The Alzheimer's Disease treatment market is known for its vast potential given the fact that there are hardly any active drugs and therapies that produce any real improvements in patients' conditions.

Longeveron Inc (NASDAQ: LGVN) is trading higher Wednesday after the company announced initiation of the Phase 2a clinical trial of lomecel-B for the treatment of Alzheimer's disease. The trial is des